Sign in with Google. Opens in new tab
D. Western Therapeutics Institute (DWTI) (4576 JP) - Q1 Follow-Up - June 3, 2025
SUMMARY
- SIR believes DWTI has entered an exciting new phase given significant advances in pipeline development achieved over the last year.
- Key advances included: 1) publishing favorable topline results of in-house H-1337 PIIb US trials (strong prospects as “first choice as a second-line Glaucoma drug”)
- 2) commenced jointly developed Japan PII clinical trials of regenerative medicine cell therapy DWR-2206 with ActualEyes, and successfully completing all transplants
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- (Mostly) Asia-Pac M&A: Santos, PointsBet, New World Resources, SmartPay, SBI Sumishin Net Bank, Humm
- Weekly Deals Digest (29 Jun) - FWD, HDB, Santos, PointsBet, New World, Dickson, HKBN, OneConnect
- China Healthcare Weekly (Jun.29) - Biotech Valuation Bubble Is About to Burst, Innovent's Placement
- Last Week In Event SPACE: Krungthai Card, VIOL, Melco, Singapore Post
- Xiaomi: Sentiment Surges, Option Market Signals Overreach
Top Unpaywalled Insights
More »- [IO Technicals 2025/26] Bearish Momentum Intensifies
- "The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- Overview# 29- The Hard-Asset Reset: Buying the Pullback in Commodities
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- D. Western Therapeutics Institute (DWTI) (4576 JP) - Q1 Follow-Up - June 3, 202503 Jun 2025
x